Whales with a lot of money to spend have taken a noticeably bearish stance on Teva Pharmaceutical Indus.
Looking at options history for Teva Pharmaceutical Indus TEVA we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $153,285 and 6, calls, for a total amount of $350,229.
Expected Price Movements
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $25.0 for Teva Pharmaceutical Indus, spanning the last three months.
Analyzing Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Teva Pharmaceutical Indus's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Teva Pharmaceutical Indus's substantial trades, within a strike price spectrum from $10.0 to $25.0 over the preceding 30 days.
Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| TEVA | CALL | SWEEP | BEARISH | 06/21/24 | $10.00 | $168.1K | 9.9K | 0 |
| TEVA | PUT | SWEEP | BULLISH | 09/20/24 | $17.00 | $89.9K | 177 | 309 |
| TEVA | PUT | SWEEP | BULLISH | 01/17/25 | $17.00 | $63.3K | 1.1K | 201 |
| TEVA | CALL | SWEEP | BULLISH | 01/17/25 | $10.00 | $49.5K | 10.3K | 100 |
| TEVA | CALL | SWEEP | BEARISH | 01/16/26 | $25.00 | $39.5K | 998 | 895 |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
After a thorough review of the options trading surrounding Teva Pharmaceutical Indus, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Teva Pharmaceutical Indus Standing Right Now?
- Trading volume stands at 8,925,530, with TEVA's price up by 0.35%, positioned at $14.19.
- RSI indicators show the stock to be may be overbought.
- Earnings announcement expected in 42 days.
What The Experts Say On Teva Pharmaceutical Indus
1 market experts have recently issued ratings for this stock, with a consensus target price of $14.0.
- Showing optimism, an analyst from JP Morgan upgrades its rating to Neutral with a revised price target of $14.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Teva Pharmaceutical Indus with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
